Mayne Pharma Group Dirección

Dirección controles de criterios 2/4

El CEO de Mayne Pharma Group's es Shawn O’Brien , nombrado en Oct 2022, tiene una permanencia de 1.5 años. compensación anual total es A$1.50M, compuesta por 44.2% salario y 55.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.046% de las acciones de la empresa, por valor de A$253.01K. La antigüedad media del equipo directivo y de la junta directiva es de 2.3 años y 2.1 años, respectivamente.

Información clave

Shawn O’Brien

Chief Executive Officer (CEO)

AU$1.5m

Compensación total

Porcentaje del salario del CEO	44.2%
Permanencia del CEO	1.5yrs
Participación del CEO	0.05%
Permanencia media de la dirección	2.3yrs
Promedio de permanencia en la Junta Directiva	2.1yrs

Actualizaciones recientes de la dirección

Recent updates

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Mar 06

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Mar 01

We Think Mayne Pharma Group Limited's (ASX:MYX) CEO Compensation Package Needs To Be Put Under A Microscope

Nov 16

Mayne Pharma Group (ASX:MYX) Is Making Moderate Use Of Debt

Nov 10

Mayne Pharma Group (ASX:MYX) Is Carrying A Fair Bit Of Debt

May 17

Is Mayne Pharma Group Limited (ASX:MYX) Trading At A 37% Discount?

Mar 22

How Many Mayne Pharma Group Limited (ASX:MYX) Shares Did Insiders Buy, In The Last Year?

Mar 01

What You Need To Know About Mayne Pharma Group Limited's (ASX:MYX) Investor Composition

Feb 08

Mayne Pharma Group Limited's (ASX:MYX) Shift From Loss To Profit

Jan 18

Mayne Pharma Group's (ASX:MYX) Shareholders Are Down 75% On Their Shares

Dec 27

Would Mayne Pharma Group (ASX:MYX) Be Better Off With Less Debt?

Dec 09

A Quick Analysis On Mayne Pharma Group's (ASX:MYX) CEO Compensation

Nov 24

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Shawn O’Brien en comparación con los beneficios de Mayne Pharma Group?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-AU$274m
Sep 30 2023	n/a	n/a	-AU$296m
Jun 30 2023	AU$2m	AU$663k	-AU$317m

Compensación vs. Mercado: La compensación total ($USD968.82K) de Shawn está en línea con el promedio de empresas de tamaño similar en el mercado Australian ($USD769.02K).

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Shawn con los resultados de la empresa.

CEO

Shawn O’Brien (64 yo)

1.5yrs

Permanencia

AU$1,502,156

Compensación

Mr. Shawn Patrick O'Brien, B.Sc has been CEO, MD & Director at Mayne Pharma Group Limited since October 1, 2022. He serves as the Chief Commercial Advisor at Melanovus Oncology, Inc. Mr. O'Brien is a found...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Shawn O’Brien	CEO, MD & Director	1.5yrs	AU$1.50m	0.046% A$ 256.7k
Aaron Gray	Chief Financial Officer	1.7yrs	AU$1.30m	0.016% A$ 92.2k
Kimberly Parker	Executive VP & General Counsel	2.3yrs	sin datos	sin datos
Brant Schofield	Executive Vice President of Corporate Development	3.3yrs	AU$1.29m	sin datos
Erinn Nathaniel	Director of Global Human Resources	1.3yrs	sin datos	sin datos
Daniel Moore	Executive Vice President of Commercial	4.6yrs	sin datos	sin datos
Frank Casty	Executive VP & Global Chief Medical Officer	1.3yrs	sin datos	sin datos
Brenton Walter	Financial Controller	19.8yrs	sin datos	sin datos
Laura Loftus	Associate General Counsel & Company Secretary	4.1yrs	sin datos	sin datos

2.3yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de MYX se considera experimentado (2.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Shawn O’Brien	CEO, MD & Director	1.5yrs	AU$1.50m	0.046% A$ 256.7k
Frank Condella	Independent Non-Executive Chairman	5.9yrs	AU$297.04k	0.081% A$ 456.9k
Bruce Robinson	Independent Non-Executive Director	9.7yrs	AU$166.43k	0.039% A$ 220.0k
Patrick Blake	Independent Non-Executive Director	5.8yrs	AU$212.39k	0.027% A$ 153.1k
Ann Custin	Independent Non-Executive Director	2.1yrs	AU$212.39k	0.026% A$ 148.0k
Kathryn MacFarlane	Independent Non-Executive Director	2.2yrs	AU$212.42k	0.047% A$ 263.4k
Anne Lockwood	Director	less than a year	sin datos	sin datos
David Petrie	Independent Non-Executive Director	1.6yrs	AU$137.96k	sin datos

2.1yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de MYX no se considera experimentada (2.1 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Mayne Pharma Group Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

High number of new directors

Mayne Pharma Group Limited Approves Election of Anne Lockwood

Mayne Pharma Group Limited, Annual General Meeting, Nov 30, 2023

Independent Non-Executive Director recently bought AU$69k worth of stock

Mayne Pharma Group Limited Announces Retirement of Carolyn Myers from the Board At the End of July 2023

Independent Non-Executive Chairman recently bought AU$74k worth of stock

Recent updates

Consensus revenue estimates increase by 14%, EPS downgraded

First half 2024 earnings released: AU$0.88 loss per share (vs AU$1.38 loss in 1H 2023)

Forecast to breakeven in 2026

Mayne Pharma Group Limited to Report Fiscal Year 2024 Results on Aug 23, 2024

Mayne Pharma Group Limited to Report First Half, 2024 Results on Feb 26, 2024

High number of new directors

Consensus estimates of losses per share improve by 13%

Mayne Pharma Group Limited Approves Election of Anne Lockwood

Mayne Pharma Group Limited, Annual General Meeting, Nov 30, 2023

Independent Non-Executive Director recently bought AU$69k worth of stock

Consensus estimates of losses per share improve by 13%

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Financial data availability

Mayne Pharma Group Limited to Report Fiscal Year 2023 Results on Aug 31, 2023

Mayne Pharma Group Limited Announces Retirement of Carolyn Myers from the Board At the End of July 2023

Independent Non-Executive Chairman recently bought AU$74k worth of stock

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Consensus revenue estimates fall by 19%

Price target decreased by 24% to AU$3.86

First half 2023 earnings released: AU$0.078 loss per share (vs AU$0.62 loss in 1H 2022)

Mayne Pharma Group Limited to Report First Half, 2023 Results on Feb 28, 2023

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces US Launch of Haloette, a Generic Version of Nuvaring

Inaugural dividend of AU$0.065 per share

Consensus revenue estimates fall by 11%

Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

Analysts Just Slashed Their Mayne Pharma Group Limited (ASX:MYX) EPS Numbers

Consensus forecasts updated

Price target decreased to AU$0.37

Is Mayne Pharma Group (ASX:MYX) Using Too Much Debt?

High number of new directors

High number of new directors

Mayne Pharma Group Limited Declares Fully Franked Special Dividend, Payable on 27 January 2023

Catalent, Inc. (NYSE:CTLT) acquired Metrics, Inc. from Mayne Pharma Group Limited (ASX:MYX) for approximately $480 million.

Mayne Pharma Group Limited Announces Executive Changes Effective from 1 October 2022

Price target decreased to AU$0.40

Mayne Pharma Group Limited Announces Management Changes

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Scott Richards Plans to Retire as CEO of Mayne Pharma Group Limited

Price target increased to AU$0.43

FDA Grants Approval to Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA of the Abbreviated New Drug Application (Anda) for Haloette

Mayne Pharma Group Limited and Mithra Pharmaceuticals, Sa Announces NEXTSTELLIS Oral Contraceptive Now Available in Australia

Mayne Pharma Group Limited Announces CFO Changes

Price target decreased to AU$0.36

Is Mayne Pharma Group (ASX:MYX) A Risky Investment?

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Forecast breakeven date pushed back to 2024

First half 2022 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 97%

Mayne Pharma Expands U.S Dermatology Portfolio

Price target increased to AU$0.48

Insufficient new directors

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Therapeutic Goods Administration Approval of NEXTSTELLIS® Oral Contraceptive

We Think Mayne Pharma Group Limited's (ASX:MYX) CEO Compensation Package Needs To Be Put Under A Microscope

Mayne Pharma Group (ASX:MYX) Is Making Moderate Use Of Debt

High number of new directors

Independent Non Executive Director Bruce Mathieson has left the company

Independent Chairman Roger Corbett has left the company

Independent Chairman Roger Corbett has left the company

U.S. Food and Drug Administration Approves Mayne Pharma LEXETTE for Adolescent Plaque Psoriasis

Independent Non-Executive Director recently bought AU$137k worth of stock

Price target decreased to AU$0.42

Full year 2021 earnings released: AU$0.13 loss per share (vs AU$0.061 loss in FY 2020)

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Nextstellis Receives FDA Marketing Exclusivity and Phase Iii Data Published

Mayne Pharma Group (ASX:MYX) Is Carrying A Fair Bit Of Debt

Is Mayne Pharma Group Limited (ASX:MYX) Trading At A 37% Discount?

Mayne Pharma Announces New Data Showing Treatment with Nextstellis® Investigational Combined Oral Contraceptive (Coc) Containing Drospirenone (Drsp) and Estetrol

Mayne Pharma Group Limited Launches Another Generic Oral Contraceptive

Analysts lower EPS estimates to -AU$0.094

How Many Mayne Pharma Group Limited (ASX:MYX) Shares Did Insiders Buy, In The Last Year?